BGI
IOVA icon

B Group Inc’s Iovance Biotherapeutics IOVA Stock Holding History

B Group Inc’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.26M Hold
1,500,000
– – 3.9% 9
2025
Q4 		$4.09M Hold
1,500,000
– – 3.02% 10
2025
Q3 		$3.25M Hold
1,500,000
– – 2.39% 12
2025
Q2 		$2.58M Hold
1,500,000
– – 1.99% 12
2025
Q1 		$5M Buy
1,500,000
+508,000
+51% +$2.62M 4.28% 5
2024
Q4 		$7.34M Buy
+992,000
New +$9.2M 4.49% 5

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

B Group Inc's IOVA Position: Q1 2026 in Review

B Group Inc held its Iovance Biotherapeutics (IOVA) position steady in Q1 2026 at 1,500,000 shares worth $5.26M. The position accounts for 3.9% of the portfolio, ranked #9.

B Group Inc first reported a position in IOVA in Q4 2024 and has held it in 6 quarters since. The position peaked at $7.34M in Q4 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • B Group Inc held 1,500,000 shares of Iovance Biotherapeutics worth $5.26M as of Q1 2026.
  • B Group Inc left its Iovance Biotherapeutics share count unchanged in Q1 2026.
  • Iovance Biotherapeutics made up 3.9% of B Group Inc's portfolio in Q1 2026, its #9 holding.
  • B Group Inc first reported a position in Iovance Biotherapeutics in Q4 2024 and has held it in 6 quarters since.
  • B Group Inc's Iovance Biotherapeutics position peaked at $7.34M in Q4 2024.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on B Group Inc's 13F filing for Q1 2026, filed 15 May 2026.